Scientists discover new way to target cancer

December 12, 2011

Scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth.

The findings, published today in the journal Cancer Cell, reveal how cancer cells grow faster by producing their own .

Cancer cells gain the they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the . These proteins are vascular growth factors like VEGF — the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.

Scientists at UWE Bristol and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a in the cell to be turned on. This master switch of splicing makes grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.

In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers.

Dr Michael Ladomery spearheading the work from UWE Bristol, said: "The research clearly demonstrates that it may be possible to block tumour growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armoury of potential anti-cancer therapies."

Professor David Bates who led the team from the University of Bristol's School of Physiology and Pharmacology, said: "This enables us to develop new classes of drugs that target blood vessel growth, in cancer and other diseases like blindness and kidney disease."

The work, which started on kidney cancer, also involved groups at Southmead Hospital, where patients with kidney disease helped by allowing tissues that had been removed during surgery to be used in the research.

Professor Steve Harper, Consultant Nephrologist and part of the research team, said: "This shows how important it is for patients, doctors and scientists to come together in an excellent environment like Bristol to make these groundbreaking discoveries."

Professor Moin Saleem, Consultant Pediatric Nephrologist, whose lab helped to make the cells used, added: "We are really grateful to the patients who allowed their cells to be used in this research, as we hope it will eventually help the development of new drugs."

Explore further: New strategy to attack tumor-feeding blood vessels

More information: The paper, entitled 'WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing', is published today in Cancer Cell.

Related Stories

New strategy to attack tumor-feeding blood vessels

June 6, 2011
Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

New role for Vascular Endothelial Growth Factor in regulating skin cancer stem cells

October 19, 2011
Skin squamous cell carcinomas are amongst the most frequent cancers in humans. Recent studies suggest that skin squamous cell carcinoma, like many other human cancers, contain particular cancer cells, known as cancer stem ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.